The World Health Organization (WHO) has granted prequalification to Coartem Baby, the first malaria medication specifically developed for newborns and young infants weighing between 2 kg and 5 kg. Developed through a partnership between Novartis and the Medicines for Malaria Venture (MMV), this treatment addresses a critical gap in neonatal care where no approved therapies previously existed. This milestone, announced ahead of World Malaria Day 2026, paves the way for the large-scale procurement and distribution of life-saving medicine to the most vulnerable age groups in malaria-endemic regions.
A Milestone in Neonatal Malaria Care
For decades, newborns and young infants weighing less than 5 kg were excluded from most clinical trials, leaving healthcare providers with limited options for treating malaria in this age group. In the absence of a dedicated formulation, clinicians often had to break or crush tablets designed for older children to estimate a dose. This practice posed significant risks, including incorrect dosing that could lead to either treatment failure or dangerous toxicity.
The WHO prequalification of Coartem Baby marks a turning point in global health. This certification serves as a quality assurance stamp, confirming that the product meets international standards for safety and efficacy. Crucially, it enables international procurement agencies like UNICEF and the Global Fund to Fight AIDS, Tuberculosis and Malaria to purchase the drug in bulk for distribution in low-income and malaria-endemic nations.
The World Health Organization, established in 1948 and headquartered in Geneva, Switzerland, plays a central role in setting these global health norms. Its prequalification programme is particularly vital for countries with limited regulatory capacity, ensuring they have access to reliable and high-quality medical products.
Understanding Coartem Baby: Science and Development
Coartem Baby is an Artemisinin-based Combination Therapy (ACT), which is the gold standard for treating uncomplicated malaria caused by the Plasmodium falciparum parasite. While artemether and lumefantrine have been used for years, this specific formulation is uniquely tailored for infants. Unlike older children, neonates have immature liver functions and different metabolic rates, necessitating a precise ratio of active ingredients that was previously unavailable.
The development of the drug was supported by the CALINA study, a Phase II/III clinical trial that demonstrated its safety and effectiveness in babies weighing as little as 2 kg. To ensure adherence and ease of use, the medication is designed to be patient-friendly. It has a sweet cherry flavor to mask the natural bitterness of the medicine and is dispersible, meaning it can be dissolved in small amounts of water or breast milk for easy administration.
The project is a result of a long-term collaboration between the pharmaceutical major Novartis and the Medicines for Malaria Venture (MMV). MMV is a leading non-profit product development partnership in the field of antimalarial drug research, established in 1999 to reduce the burden of malaria in disease-endemic countries.
The Critical Burden of Malaria in Infants
Malaria remains a leading cause of mortality among children, especially in the WHO African Region, which carries a disproportionate 95% of the global malaria burden. Statistics from the World Health Organization indicate that children under five years of age account for approximately 75% of all malaria deaths worldwide. Within this demographic, infants in their first few months of life are at the highest risk of severe infection because they have not yet developed any natural immunity to the malaria parasite.
The Plasmodium falciparum parasite, primarily transmitted through the bite of infected female Anopheles mosquitoes, is responsible for the most severe forms of the disease. In regions where transmission is high, newborns often face a “treatment desert” due to the lack of specialized pediatric formulations. The introduction of Coartem Baby is expected to significantly reduce neonatal mortality by providing a safe, tested, and easy-to-administer therapeutic option.
Novartis and the Global Health Partnership
The development of Coartem Baby is a cornerstone of the Novartis Malaria Initiative, one of the pharmaceutical industry’s largest access-to-medicine programmes. Novartis, a Swiss multinational pharmaceutical corporation headquartered in Basel, Switzerland, has committed to providing this treatment on a not-for-profit basis for public sector use in malaria-endemic nations. This ensures that the medicine reaches the most vulnerable populations without the barrier of prohibitive costs.
The project highlights the success of the Product Development Partnership (PDP) model, involving the Medicines for Malaria Venture (MMV). MMV, based in Geneva, Switzerland, was established in 1999 to bridge the gap between public health needs and private sector research. This collaboration has successfully navigated the clinical and regulatory hurdles required to bring a neonatal-specific drug to market, ensuring that even the smallest patients have a dedicated therapeutic solution.
India’s Roadmap to Malaria Elimination
India has made remarkable strides in its fight against the disease, achieving an estimated 80% reduction in malaria cases and deaths between 2015 and 2023. The country has set a clear target to achieve a malaria-free status by 2030, with an intermediate goal of reaching zero indigenous cases by 2027. This involves a multi-pronged strategy led by the National Center for Vector Borne Diseases Control (NCVBDC), focusing on intensive surveillance and vector control.
| Aspect | National Malaria Elimination Framework |
|---|---|
| Parent Goal | Global Technical Strategy for Malaria 2016-2030 |
| National Target | Complete Elimination by 2030 |
| Intermediate Goal | Zero indigenous cases by 2027 |
| Nodal Agency | National Center for Vector Borne Diseases Control |
| Strategy | High-burden to high-impact (HBHI) approach |
Key Takeaways
- The World Health Organization (WHO) has prequalified Coartem Baby, making it the first antimalarial specifically approved for newborns and infants weighing between 2 kg and 5 kg.
- Coartem Baby is an Artemisinin-based Combination Therapy (ACT) consisting of artemether and lumefantrine, specifically formulated to account for the immature liver function of neonates.
- The medication is a dispersible tablet with a cherry flavor, developed through a partnership between Novartis (headquartered in Basel, Switzerland) and the Medicines for Malaria Venture (MMV).
- WHO Prequalification acts as a quality benchmark that allows international procurement bodies such as UNICEF and the Global Fund to purchase and distribute the drug in bulk.
- India’s National Framework for Malaria Elimination targets achieving zero indigenous cases by 2027 and a complete malaria-free status by 2030.
- World Malaria Day is commemorated globally on April 25 each year to highlight the progress and challenges in the fight against the disease.
